



OPEN ACCESS

EDITED BY

Michel Grothe,
Fundacion Centro De Investigacion De
Enfermedades Neurologicas, Spain

REVIEWED BY

Tomas Leon,
Del Salvador Hospital, Chile
Carla Abdelnour,
Stanford University, United States

*CORRESPONDENCE

Wenjun Zhou
✉ zhouwenjun@shansier.com
Jie Zhang
✉ zhangjie@shansier.com

†These authors have contributed equally to
this work

†The Alzheimer's Disease Neuroimaging
Initiative (ADNI) unites researchers with study
data as they work to define the progression of
Alzheimer's disease. ADNI researchers collect,
validate and utilize data such as MRI and PET
images, genetics, cognitive tests, CSF and
blood biomarkers as predictors for the
disease. For more details, please visit [http://
adni.loni.usc.edu/wp-content/uploads/how_
to_apply/ADNI_Acknowledgement_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

RECEIVED 01 April 2024

ACCEPTED 29 July 2024

PUBLISHED 12 August 2024

CITATION

Wang X, Ye T, Jiang D, Zhou W and
Zhang J (2024) Characterizing the clinical
heterogeneity of early symptomatic
Alzheimer's disease: a data-driven machine
learning approach.
Front. Aging Neurosci. 16:1410544.
doi: 10.3389/fnagi.2024.1410544

COPYRIGHT

© 2024 Wang, Ye, Jiang, Zhou and Zhang.
This is an open-access article distributed
under the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that
the original publication in this journal is cited,
in accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Characterizing the clinical heterogeneity of early symptomatic Alzheimer's disease: a data-driven machine learning approach

Xiwu Wang^{1†}, Teng Ye^{2†}, Deguo Jiang¹, Wenjun Zhou^{3*} and
Jie Zhang^{4*} for the Alzheimer's Disease Neuroimaging Initiative[†]

¹Department of Psychiatry, Wenzhou Seventh People's Hospital, Wenzhou, China, ²Department of
Ultrasound, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ³Research
and Development, Hangzhou Shansier Medical Technologies Co., Ltd., Hangzhou, China,
⁴Department of Data Science, Hangzhou Shansier Medical Technologies Co., Ltd., Hangzhou, China

Introduction: Alzheimer's disease (AD) is highly heterogeneous, with substantial individual variabilities in clinical progression and neurobiology. Amyloid deposition has been thought to drive cognitive decline and thus a major contributor to the variations in cognitive deterioration in AD. However, the clinical heterogeneity of patients with early symptomatic AD (mild cognitive impairment or mild dementia due to AD) already with evidence of amyloid abnormality in the brain is still unknown.

Methods: Participants with a baseline diagnosis of mild cognitive impairment or mild dementia, a positive amyloid-PET scan, and more than one follow-up Alzheimer's Disease Assessment Scale-Cognitive Subscale-13 (ADAS-Cog-13) administration within a period of 5-year follow-up were selected from the Alzheimer's Disease Neuroimaging Initiative database ($n=421$; age = 73 ± 7 ; years of education = 16 ± 3 ; percentage of female gender = 43%; distribution of APOE4 carriers = 68%). A non-parametric k-means longitudinal clustering analysis in the context of the ADAS-Cog-13 data was performed to identify cognitive subtypes.

Results: We found a highly variable profile of cognitive decline among patients with early AD and identified 4 clusters characterized by distinct rates of cognitive progression. Among the groups there were significant differences in the magnitude of rates of changes in other cognitive and functional outcomes, clinical progression from mild cognitive impairment to dementia, and changes in markers presumed to reflect neurodegeneration and neuronal injury. A nomogram based on a simplified logistic regression model predicted steep cognitive trajectory with an AUC of 0.912 (95% CI: 0.88 – 0.94). Simulation of clinical trials suggested that the incorporation of the nomogram into enrichment strategies would reduce the required sample sizes from 926.8 (95% CI: 822.6 – 1057.5) to 400.9 (95% CI: 306.9 – 516.8).

Discussion: Our findings show usefulness in the stratification of patients in early AD and may thus increase the chances of finding a treatment for future AD clinical trials.

KEYWORDS

Alzheimer's disease, heterogeneity, cognitive trajectories, longitudinal clustering, subtypes

Introduction

Alzheimer's disease (AD) is a heterogeneous disorder with high individual variabilities in cognitive progression (Jutten et al., 2021; Cohen et al., 2024). In the search for treatment, people have so far predominantly targeted one single clinical entity and assumed that individuals are homogeneous in the course of cognitive decline and the placebo and treatment groups should demonstrate equal rates of cognitive deterioration if the treatment is ineffective (Fogel, 2018). Nevertheless, several longitudinal studies have found substantial variations in the rates of cognitive decline among patients with AD despite being matched for clinical severity at the beginning of the study (Jack et al., 2010b; van Rossum et al., 2012; Vos et al., 2015; Scheltens et al., 2018). A consequence is that cognitive heterogeneity may bias the results of therapeutic clinical trials of AD. For instance, even though within most previous trials no difference between placebo and treatment groups was observed, we cannot fully rule out the probability that the null effect was actually attributed to over-representation of individuals with slow rates of cognitive decline in the treatment group or over-representation of individuals with rapid rates of cognitive decline in the placebo group, if treatments were actually effective (Jutten et al., 2021). Moreover, a specific therapeutic strategy may only benefit certain subgroups of patients, and thus identification of meaningful subgroups of individuals with AD may be a crucial first step towards improving the clinical trial design, increasing the chance of finding an efficacious treatment and developing personalized medicine.

One strategy to identify subtypes is to categorize patients based on cognitive features using empirical methods in a non-biased manner (Gamberger et al., 2017; Lee et al., 2018; Kim et al., 2019, 2022; Blanken et al., 2020; Edmonds et al., 2021; Giraldo et al., 2021; Wang et al., 2023; Kim B. S. et al., 2023; Kim Y. J. et al., 2023). For cross-sectional neuropsychological data, several previous studies utilized a data-driven approach to sort out the cognitive heterogeneity of AD by applying clustering methods, leading to the identification of differential cognitive subtypes (Scheltens et al., 2015, 2017; Qiu et al., 2019). However, cross-sectional cognitive data can only capture the heterogeneity in cognitive deficits at a snapshot and are unable to delineate the temporal nature of disease progression. For these reasons, several investigators (Geifman et al., 2017; Ziegler et al., 2020; Levine et al., 2021) have undertaken subtyping approaches to understand the heterogeneity of AD by using repeatedly measured cognitive outcomes, namely Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), which is a commonly used primary endpoint in clinical trials of AD. In Geifman et al.'s study (Geifman et al., 2017), latent class mixed modeling (LCMM) has been conducted to successfully identify 3 distinct longitudinal cognitive subgroups (i.e., rapid decliners, slow decliners, and severely-impaired slow decliners) over a period of 18 months in a clinical trial database involving clinically diagnosed AD dementia patients (Geifman et al., 2017). In Ziegler et al.'s study (Ziegler et al., 2020), a statistical clustering method has been performed to identify 3 different cognitive subgroups (i.e., "mild impairment" group, "memory impaired" group, and "fast progressing" group) over a period of 2 years among patients with a clinical diagnosis of AD dementia. More recently, by leveraging data from five clinical trials of donepezil for AD patients, Levine et al. (2021) performed a latent class model to identify 3 subgroups (i.e., low scorers, improvers, and high scorers) over a period of 12 weeks.

Nevertheless, despite the shift from a syndromal definition to a biological definition of AD in observational and interventional research, and AD clinical trials are moving earlier in the disease process (Jack et al., 2018), no studies have yet investigated the cognitive heterogeneity of early symptomatic AD [mild cognitive impairment (MCI) or mild dementia due to AD] with evidence of abnormal amyloid in the brain. We undertook such a study, using repeatedly measured longitudinal cognitive outcomes over a period of 5 years to identify classifications of patients with early AD that show distinct clinical progression trajectories.

In this study, we expanded upon previous research by applying a state-of-the-art statistical clustering method to longitudinal ADAS-Cog-13 data collected within a 5-year period from patients with early AD who showed evidence of abnormal amyloid and met inclusion and exclusion criteria commonly applied in a typical clinical trial involving patients with early AD (van Dyck et al., 2023). Following the clustering analysis, we examined associations of the identified cognitive trajectories with changes in other cognitive and functional measures, neurogenerative biomarkers, *in vivo* CSF AD biomarkers, and disease progression to AD dementia. We investigated potential baseline predictors that may be associated with membership in the identified subtypes. Finally, a nomogram was created to facilitate an easy and practical prediction of probabilities of experiencing steep cognitive decline, and simulated clinical trials were conducted to examine whether the incorporation of the nomogram into the enrichment strategy would lead to the reduction of sample size for trials involving early AD.

Materials and methods

Study participants

Data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.¹ ADNI is a multicenter longitudinal cohort study with the main research goal of examining whether clinical, neuropsychological, biological, and other neuroimaging markers can be combined to track clinical progression in the Alzheimer's disease continuum. The ADNI study was approved by an ethical review board of participating study centers and all subjects provided written informed consent.

For the current study, we selected subjects with a baseline clinical diagnosis of either MCI or mild AD dementia who had elevated amyloid as determined by PET imaging (specific methods and cutoff described below) and had at least 1 follow-up measurement available (with ADAS-Cog-13 administration) the next 5 years. Criteria for MCI were (1) memory complaint; (2) abnormal memory function evidenced by the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale-Revised; (3) Mini-Mental State Examination (MMSE) score ≥ 24 ; (4) global Clinical Dementia Rating (CDR) score of 0.5; (5) absence of dementia. Criteria for mild AD dementia were (1) memory complaint; (2) abnormal memory function evidenced by the Logical Memory II subscale from the Wechsler Memory Scale-Revised; (3) MMSE score between 20–26

¹ <https://adni.loni.usc.edu/>

(inclusive); (4) global CDR score of 0.5 or 1; (5) NINCDS/ADRDA criteria for probable AD dementia (Mckhann et al., 1984). This study included 421 participants with early AD (MCI or mild dementia due to AD). The inclusion criteria for participants with early AD in the current study largely aligned with those used in a recent anti-amyloid AD clinical trial (van Dyck et al., 2023). For detailed sample selection procedures, please see Figure 1.


Clustering cognitive variable

The ADAS-Cog (Rosen et al., 1984) is a commonly used cognitive outcome for tracking disease progression and measuring the efficacy of antedementia treatments and the most used cognitive outcome measure in AD clinical trials (Cano et al., 2010). Thus, we treated ADAS-Cog as our primary cognitive outcome and used it as the variable for longitudinal cluster analysis (specific procedures for cluster analysis described below). The 13-item version of ADAS-Cog

(ADAS-Cog-13) includes 13 tasks that primarily assess the cognitive domains of episodic memory, praxis, and language. Total score ranges from 0 to 85, with higher scores indicating greater cognitive impairment (Rosen et al., 1984).

Other cognitive measures

Apart from the ADAS-Cog, the second and third most frequently used cognitive outcome measures in AD clinical trials were the MMSE (Folstein et al., 1975) and the CDR-sum of boxes (CDR-SB) (Williams et al., 2013; Jutten et al., 2021). The Functional Activities Questionnaire (FAQ) (Pfeffer et al., 1982) is a commonly used instrumental activities of daily living (IADLs) scale that predicts clinical progression (Marshall et al., 2015). Therefore, these cognitive measures (i.e., MMSE, CDR-SB, and FAQ) were taken to assess and validate cognitive and functional changes over time between different cognitive subgroups. The MMSE is a widely used global cognitive screening test,



with total scores ranging from 0 to 30, and a lower score indicates greater cognitive impairment (Folstein et al., 1975). The CDR-SB captures 6 cognitive and functional domains, including memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care (Williams et al., 2013). Scores for each domain range from 0 to 3, with higher scores reflecting greater impairment. Adding scores of each domain leads to a total score, which ranges from 0 to 18 (Williams et al., 2013). The FAQ rates 10 functional domains, with total scores ranging from 0 to 30, and higher scores indicate greater impairment (Pfeffer et al., 1982).

Determination of amyloid positivity

Amyloid status (amyloid negative vs. amyloid positive) was determined based on Pittsburgh compound B (PiB) or Florbetapir AV-45 PET imaging (summarized data were pulled from the ADNI Laboratory of Neuroimaging database: ida.loni.usc.edu; the file name is ADNIMERGE.csv). Amyloid positivity was determined by calculating the standardized uptake value ratio of the mean uptake in four cortical regions (frontal, cingulate, parietal, and temporal cortices), which was normalized to the uptake in the entire cerebellum. We used validated tracer-specific cutoff values to determine abnormality, which were > 1.47 for PiB-PET and > 1.10 for AV45-PET (Landau et al., 2013).

Neurodegenerative markers

Hippocampal atrophy, ventricular enlargement, and cerebral glucose hypometabolism are presumed to reflect neurodegenerative alterations most proximal to the onset of cognitive decline, and valid predictors of disease progression (Jack et al., 2004, 2010a). Therefore, we took these three imaging markers to characterize neurodegenerative changes among cognitive subgroups. Summary data were obtained from the ADNI Laboratory of Neuroimaging database: ida.loni.usc.edu; the file name is ADNIMERGE.csv. The proportional approach [(normalization of regional volumes by intracranial volume (ICV))] was taken to adjust sex differences in head size since women and men differ substantially in ICV. Adjusted ventricular volume (aVV) was calculated using the following equation: $aVV = \text{ventricular/intracranial volume} \times 10^3$. Adjusted hippocampal volume (aHV) was calculated using the following equation: $aHV = \text{hippocampal/intracranial volume} \times 10^3$. Cerebral glucose metabolism was measured by Fludeoxyglucose PET (FDG-PET). The global FDG SUVRs were measured by calculating the mean FDG uptake in three brain regions (posterior cingulate, angular gyri, and inferior temporal gyri), which was normalized to the uptake in the pons and cerebellum.

CSF AD biological markers

Lumbar puncture was conducted as described in the ADNI manual.² The levels of CSF AD biomarkers, including CSF A β 1–42

(A β 42), total tau (t-tau), and phosphorylated-tau at threonine 181 (p-tau), were measured by the Roche Elecsys A β 42 CSF, Elecsys t-tau CSF, and Elecsys p-tau CSF immunoassays at the Biomarker Research Laboratory, University of Pennsylvania, USA, as previously described (Bittner et al., 2016). In this study, Elecsys A β 42 values >1700 pg./mL (upper technical limit) were fixed at 1700 pg./mL. CSF A β 42 values below 1,098 pg./mL were used to classify individuals as amyloid-positive, based on thresholds established in a previous study (Schindler et al., 2018).

Statistical analyses


Statistical work and data visualization were conducted using R version 4.1.2 (Team, R.Core, 2014).

First, to identify distinct longitudinal cognitive profiles, a non-parametric k-means longitudinal clustering method from the R package “kml” (Genolini et al., 2015) was used to detect the ADAS-Cog-13 trajectories over a 5-year follow-up period. This method allows for the investigation of how a parameter of interest changes over time and categorizes individual trajectories into distinct groups of participants with homogeneous characteristics. The ADAS-Cog-13 was treated as our clustering variable given its predominant role in AD clinical trials. In the cluster analysis, we only included participants who had undergone at least one follow-up assessment using ADAS-Cog-13 within 5 years since baseline. K-means is an algorithm in the expectation–maximization (EM) (Celeux and Govaert, 1992) class that utilizes a hill-climbing approach. EM algorithms initially assign each observation to a cluster and then achieve optimal clustering by alternating between two phases. In the expectation phase, the centers of the different clusters (known as seeds) are computed. The maximization phase involves assigning each observation to its “nearest cluster.” The alternating between the two phases is repeated until no further changes occur in the clusters. Models were constructed for 1 to 8 clusters, and the 4-cluster solution was chosen based on several factors, including the Bayesian information criterion (BIC) (Schwarz, 1978), the elbow method, and ensuring that each cluster had an adequate sample size. The graph showing the BIC per cluster solution is provided in Supplementary Figure S1. The individual trajectories and resulting 4-cluster trajectories are shown in Figure 2A.

Second, the differences in demographics, APOE4 genotype, clinical diagnosis, cognitive evaluations, neurodegenerative markers, and CSF AD biological markers between 4 clusters at baseline were compared. We used analysis of variance (ANOVA) to assess differences between clusters for continuous variables and Pearson's χ^2 tests for categorical variables. If group differences were detected using ANOVA or Pearson's χ^2 tests, we performed pairwise t-tests or χ^2 tests in *post hoc* analyses and corrected for multiple testing using the false discovery rate (FDR) correction (Benjamini and Hochberg, 1995). To demonstrate group comparisons of means, we also presented visual representations, as shown in Figure 3.

Third, to characterize the longitudinal changes over a 5-year follow-up period in cognitive measures, neurodegenerative markers, and CSF AD biological markers for each cluster, linear mixed-effects models were built using the R package “lme4” (Bates et al., 2014). We constructed nine models for the dependent variables, including MMSE, CDR-SB, FAQ, aVV, aHV, FDG SUVRs, CSF A β 42, t-tau, and p-tau. These models included time since baseline (in years), clusters,

² www.adni-info.org



and their interaction as fixed effects, and age, gender, years of education, APOE4 status, and their interactions with time as covariates. Additionally, a random intercept was included for each participant in all models. Each model was fit using maximum likelihood, which is a method used to estimate the parameters of a statistical model by finding the parameter values that maximize the likelihood function. We also used Satterthwaite's method to estimate the degrees of freedom in the t-tests, which allowed us to test the significance of the fixed effects and calculate the 95% confidence intervals. The models can be summarized as the following equations: $Y_{change} \sim Clusters * time + Age * time + Gender * time + Education * time + APOE4\ status * time$. Y_{change} represents the annual change in the aforementioned nine dependent variables from the baseline. To further understand the differences in slopes among the four cluster groups, we conducted pairwise comparisons between clusters using estimated marginal means (EMMs). To adjust for multiple testing, we applied the FDR method for correction.

Fourth, the bootstrap was used to quantify the uncertainty associated with the coefficients and to test the robustness of the results from the aforementioned linear mixed-effects models. We generated

1,000 bootstrapped samples by randomly resampling the data with replacement and refitting the linear mixed-effects models. The random effects were included to generate bootstrapped samples and a semiparametric bootstrap method was performed. The bootstrapped estimates were used to estimate the sampling distribution of the fixed effects, and the 95% confidence intervals (CIs) for the fixed effects were also calculated. A forest plot demonstrating the effect difference relative to Cluster 1 (the reference group) was also created to conduct bootstrap inference.

Fifth, to examine whether cluster membership was predictive of progression from MCI to dementia over a 5-year follow-up period, a Kaplan-Meier plot was utilized to demonstrate the conversion rate to dementia in the four clusters, and log-rank tests were employed to carry out pairwise comparisons of the survival curves and the FDR method was used to correct for multiple testing. Initially, we segregated MCI participants from each cluster, yielding a sample size of 130 in Cluster 1, 119 in Cluster 2, 40 in Cluster 3, and 2 in Cluster 4. Due to the limited number of MCI participants in Cluster 4, we merged MCI participants from Clusters 3 and 4 into a revised Cluster 3. Subsequently, we performed survival analysis utilizing the newly configured cluster




FIGURE 3

Cluster comparison on baseline cognitive measures, neurogenerative makers, and CSF AD pathologies. Panel (A): MMSE as the outcome. Panel (B): CDR-SB as the outcome. Panel (C): FAQ as the outcome. Panel (D): aVV as the outcome. Panel (E): aHV as the outcome. Panel (F): FDG SUVRs as the outcome. Panel (G): CSF A β 42 as the outcome. Panel (H): CSF t-tau as the outcome. Panel (I): CSF p-tau as the outcome. Notes: *P* values were adjusted by the FDR method. Abbreviations: MMSE: Mini-Mental State Examination; CDR-SB: Clinical Dementia Rating-sum of boxes; FAQ: Functional Activities Questionnaire; aVV: Adjusted ventricular volume; aHV: Adjusted hippocampal volume; FDG: fludeoxyglucose; A β : β -amyloid; t-tau: total tau; p-tau: phosphorylated tau.

variable (consisting of 3 clusters) as the primary predictor. The duration of follow-up was calculated as the interval between the baseline evaluation and the diagnosis of dementia at the last visit. For those subjects who did not develop dementia during the 5-year follow-up period, their data were censored at the time of their last visit.

Sixth, to estimate associations between baseline predictors and cluster membership, multivariable multinomial logistic regression models by the R package “nnet” (Venables and Ripley, 2002) were

performed, with Cluster 1 as the reference category. To handle missing values among predictors, 5 complete-data replicates were computed by Multivariate Imputation by Chained Equations using the R package “mice” (Buuren and Groothuis-Oudshoorn, 2011). The overall variable-level missingness is shown in Table 1. We imputed a score using the “predictive mean matching” method, and the imputation model included all predictors that were part of the multinomial logistic regression models, while the outcome variable (cluster

TABLE 1 Baseline characteristics by cluster.

Characteristic	Overall N = 421	Cluster 1 N = 131	Cluster 2 N = 141	Cluster 3 N = 108	Cluster 4 N = 41	p-value
Age, years	73 (7)	72 (7)	73 (7)	75 (7) ^a	72 (9) ^c	0.035
Education, years	16 (3)	16 (3)	16 (3)	16 (3)	16 (3)	0.12
Female gender, n (%)	183 (43%)	59 (45%)	60 (43%)	43 (40%)	21 (51%)	0.6
APOE4 carriers, n (%)	287 (68%)	80 (61%)	100 (71%)	77 (71%)	30 (73%)	0.2
Clinical diagnosis, n (%)						<0.001
MCI	291 (69%)	130 (99%)	119 (84%)	40 (37%)	2 (4.9%)	
Mild AD	130 (31%)	1 (0.8%)	22 (16%) ^a	68 (63%) ^{ab}	39 (95%) ^{abc}	
Follow-up duration, years	2.55 (1.55)	3.55 (1.37)	2.71 (1.53) ^a	1.66 (1.07) ^{ab}	1.13 (0.66) ^{abc}	<0.001
MMSE	26 (3)	28 (2)	27 (2) ^a	24 (3) ^{ab}	22 (2) ^{abc}	<0.001
CDR-SB	2.45 (1.80)	1.17 (0.84)	2.00 (1.22) ^a	3.57 (1.64) ^{ab}	5.07 (1.68) ^{abc}	<0.001
FAQ	6 (7)	2 (3)	5 (5) ^a	10 (7) ^{ab}	15 (7) ^{abc}	<0.001
Missing, n	3	1	1	0	1	
aVV	27 (13)	24 (12)	26 (12)	31 (12) ^{ab}	35 (14) ^{abc}	<0.001
Missing, n	28	5	11	10	2	
aHV	4.34 (0.75)	4.84 (0.71)	4.31 (0.67) ^a	3.91 (0.62) ^{ab}	3.92 (0.51) ^{ab}	<0.001
Missing, n	43	9	17	12	5	
FDG-PET	1.15 (0.17)	1.28 (0.13)	1.16 (0.13) ^a	1.07 (0.13) ^{ab}	0.92 (0.15) ^{abc}	<0.001
Missing, n	8	2	2	4	0	
CSF Aβ42, pg/ml	726 (282)	877 (345)	685 (221) ^a	643 (214) ^a	586 (178) ^a	<0.001
Missing, n	74	21	25	19	9	
Aβ positivity based on CSF Aβ42						<0.001
Aβ-	32 (9.2%)	25 (23%)	5 (4.3%)	2 (2.2%)	0 (0%)	
Aβ+	315 (91%)	85 (77%)	111 (96%) ^a	87 (98%) ^a	32 (100%) ^a	
Missing, n	74	21	25	19	9	
CSF t-tau, pg/ml	348 (145)	290 (126)	354 (143) ^a	382 (142) ^a	435 (157) ^{ab}	<0.001
Missing, n	74	21	25	19	9	
CSF p-tau, pg/ml	35 (16)	28 (14)	36 (16) ^a	38 (15) ^a	43 (16) ^{ab}	<0.001
Missing, n	74	21	25	19	9	
AV45 PET	1.41 (0.18)	1.32 (0.16)	1.41 (0.17) ^a	1.46 (0.17) ^{ab}	1.52 (0.16) ^{abc}	< 0.001
Missing, n	12	3	6	1	1	
PiB PET	1.91 (0.26)	1.63 (0.18)	2.00 (0.24)	1.95 (NA)	2.06 (0.23)	0.2
Missing, n	409	128	135	107	39	

For continuous variables, the mean and standard deviation are used to summarize the data, while for categorical variables, the data are expressed as counts and percentages. We used ANOVA to compare continuous variables and Pearson's chi-squared tests to compare categorical variables between the four clusters. In case of significant differences detected by ANOVA or Pearson's chi-squared tests, pairwise t-tests or chi-squared tests were used in post hoc analyses with FDR correction for multiple testing. APOE, Apolipoprotein E; MCI, Mild cognitive impairment; AD, Alzheimer's disease; MMSE, Mini-Mental State Examination; CDR-SB, Clinical Dementia Rating-sum of boxes; FAQ, Functional Activities Questionnaire; aVV, Adjusted ventricular volume; aHV, Adjusted hippocampal volume; FDG, fludeoxyglucose; Aβ, β-amyloid; t-tau, total tau; p-tau, phosphorylated tau. AV45, Florbetapir; PiB, Pittsburgh Compound B.

^aFDR-adjusted $p < 0.05$ compared with Cluster 1.

^bFDR-adjusted $p < 0.05$ compared with Cluster 2.

^cFDR-adjusted $p < 0.05$ compared with Cluster 3.

membership) was not included in the predictor matrix of the imputation scheme. The multinomial logistic regression modeling was then applied to the 5 imputed data sets and results were pooled utilizing Rubin's rules to yield estimates and confidence intervals that incorporate the imputed values' uncertainty (Rubin, 1989). A total of four multinomial logistic regression models with cluster membership as the dependent variable were constructed: the base model included age, gender, years of education, APOE4 genotype, and clinical diagnosis as predictor variables; the cognition model included all the

predictors from the base model and additionally incorporated MMSE; the neurodegeneration model further included aHV and FDG-PET at the basis of the cognition model; the AD biomarker model included all the predictors from the neurodegeneration model and additionally incorporated CSF Aβ42 and p-tau proteins. Adjusted odds ratios (ORs) with 95% CIs were computed for all other three clusters by comparing them with Cluster 1 (the reference category).

Seventh, given that cluster 1 showed negligible decline and cluster 2 only exhibited a slightly higher decline, while clusters 3 and 4

demonstrated similar rates of cognitive decline, we decided to combine clusters 1 and 2 into a group called “non/slow decliners,” and merge clusters 3 and 4 into a group referred to as “steep decliners.” Binary logistic regression models were built with same predictors included in the AD biomarker model and the two groups (non/slow decliners vs. steep decliners) as the outcome. To select the predictors that explain the bulk of variance in cognitive decline and create a simplified model for practicality, we employed a fast backward variable selection method (Lawless and Singhal, 1978), using the total residual Akaike’s information criterion (AIC) (Akaike, 1974) as the stopping rule. A nomogram was created to facilitate an easy and visual estimation of probabilities of steep cognitive decline based on the reduced model. Finally, in order to examine whether the inclusion of our nomogram for enrichment can reduce sample size, simulation of clinical trials were performed using the longpower R package, with a 25% treatment effect on cognitive performance over time, a statistical power of 80%, 1:1 allocation of placebo and treatment groups, and a total duration of 18 months with cognitive assessments at 0, 3, 6, 9, 12, 15, and 18 months. Bootstrap with 500 iterations was conducted.

Results

Findings of longitudinal cluster analysis

Four clusters were identified. Figure 2A demonstrates the categorization of participants with symptomatic early AD based on their ADAS-Cog-13 trajectories over a 5-year follow-up period into the following clusters: Cluster 1 ($n=131$, 31%), characterized by stable cognitive performance; Cluster 2 ($n=141$, 34%), characterized by a mild cognitive decline; Clusters 3 ($n=108$, 26%) and 4 ($n=41$, 9%), characterized by moderate to rapid rates of cognitive decline, with Cluster 4 showing more impaired cognitive performance at baseline and greater rates of cognitive decline than Cluster 3 as shown by the intercepts and slopes.

Baseline cluster characteristics

As shown in Table 1 and Figures 2B–D, 3, the baseline sociodemographic and clinical characteristics were compared between clusters. For age, Cluster 3 was older than Cluster 1, and Cluster 4 was younger than Cluster 3, but no other pairwise difference was observed. For years of education, APOE4 status (Figure 2B), and gender (Figure 2C), clusters did not differ significantly. For clinical diagnosis (Figure 2D), the distribution of mild AD dementia was significantly different between each cluster, with Cluster 4 having the highest percentage of patients with mild AD dementia. For follow-up duration, four clusters differed significantly, with Cluster 1 having the longest follow-up duration. Regarding cognitive and functional measures, all tests (MMSE, CDR-SB, and FAQ) showed significant differences between the four clusters. For neurodegenerative markers (aVV, aHV, and FDG-PET), four clusters showed significant differences, except no difference in aVV between clusters 1 and 2 and no difference in aHV between clusters 3 and 4. Regarding CSF A β 42 levels, Clusters 2–4 had lower levels of CSF A β 42 than Cluster 1, while no other pairwise difference was observed. Regarding CSF tau proteins, Clusters 2–4 had higher levels of CSF t-tau and p-tau than

Cluster 1, and Cluster 4 had higher levels of CSF t-tau and p-tau than Cluster 2, while no other pairwise difference was observed.

Associations of cluster membership with longitudinal changes in cognitive measures, neurodegenerative markers, and CSF AD biological markers

The results of the linear mixed-effects models, which investigated the relationship between cluster membership and longitudinal changes in other cognitive measures, neurodegenerative markers, and CSF AD pathologies over a 5-year follow-up period, are presented in Table 2 and Figure 4.

Concerning the models that involve cognitive and functional assessments (MMSE, CDR-SB, and FAQ), our analysis revealed that Clusters 2 through 4 experienced significantly greater decline (or worsening) relative to Cluster 1 (refer to Table 2 and Figures 4A–C). Utilizing EMMs for pairwise comparisons, we observed that the differences in slopes were statistically significant between each cluster (with all FDR-adjusted p -values being less than 0.0001).

For the aVV model (see Table 2 and Figure 4D), the cluster \times time interactions were all significant, indicating that Clusters 2–4 had greater slopes (i.e., faster rates of ventricular enlargement) compared to Cluster 1. Pairwise comparisons showed that the slope difference was significant between each cluster (all FDR-adjusted $p < 0.0001$). For the aHV model (see Table 2; Figure 4E), the cluster \times time interactions were all significant, indicating that Clusters 2–4 had steeper slopes (i.e., faster rates of hippocampal atrophy) compared to Cluster 1. Pairwise comparisons showed that the slope difference was significant between each cluster (all FDR-adjusted $p < 0.05$), except for a comparable level between Clusters 3 and 4 (FDR-adjusted $p = 0.289$). For the FDG-PET model (see Table 2 and Figure 4F), Clusters 2 and 3, but not Cluster 4, had steeper slopes (i.e., faster decline in brain glucose metabolism) compared to Cluster 1. Pairwise comparisons showed that the slope difference was significant between Clusters 1 and 2 (FDR-adjusted $p = 0.0026$), and between Clusters 1 and 3 (FDR-adjusted $p = 0.007$), while no other pairwise comparison was significant (all FDR-adjusted $p > 0.05$).


Regarding the models that involve CSF AD biological markers (CSF A β 42, t-tau, and p-tau levels), the cluster \times time interactions were not significant, except for a slope difference on CSF p-tau between Clusters 4 and 1 (see Table 2 and Figures 4G–I). These findings suggested that the changes in CSF AD biomarkers over time were consistent across clusters, with the exception of CSF p-tau, where a difference in the rate of change was observed between Clusters 4 and 1. Pairwise comparisons showed that there were significant slope differences in CSF p-tau between Clusters 4 and 1 (FDR-adjusted $p = 0.04$), and between Clusters 4 and 2 (FDR-adjusted $p = 0.04$), while no other pairwise comparison was significant (all FDR-adjusted $p > 0.05$).

Additionally, a semiparametric bootstrap method was performed to quantify the uncertainty associated with the coefficients and to test the robustness of the results from the linear mixed-effects models (Supplementary Figure S2). For example, as shown in Supplementary Figures S2A–C, the findings from the models involving cognitive and functional measures can further be evidenced by visually examining the forest plots showing the slope difference relative to Cluster 1 (the reference group). The plots demonstrate how much the effect of

TABLE 2 Summary of linear mixed effects models.

Predictors	Coefficients	SE	p-value	Coefficients	SE	p-value	Coefficients	SE	p-value
	MMSE			CDR-SB			FAQ		
Age × time	0.00517	0.00543	0.34103	0.00501	0.00318	0.115	−0.00853	0.00906	0.3468
Female gender × time	−0.03209	0.07337	0.66196	0.04473	0.04344	0.303	0.14227	0.12266	0.2463
Education × time	−0.00308	0.01374	0.82277	−0.00768	0.00818	0.348	−0.02221	0.02299	0.3342
APOE4 carriers × time	−0.09874	0.07737	0.20211	0.07859	0.04563	0.085	0.34530	0.12932	0.0077
Cluster 2 × time	−0.76090	0.07896	< 0.001	0.68107	0.04656	< 0.001	1.63580	0.13178	< 0.001
Cluster 3 × time	−2.67502	0.12525	< 0.001	1.58459	0.07449	< 0.001	3.72023	0.20776	< 0.001
Cluster 4 × time	−4.97333	0.29352	< 0.001	3.04552	0.17219	< 0.001	5.22412	0.49006	< 0.001
	aVV			aHV			FDG SUVrs		
Age × time	0.00450	0.00739	0.543	−0.00186	0.00068	0.0059	0.00005	0.00038	0.89570
Female gender × time	−0.09106	0.09402	0.333	−0.02882	0.00889	0.0012	−0.00857	0.00499	0.08743
Education × time	0.01274	0.01694	0.452	0.00307	0.00167	0.0667	−0.00009	0.00087	0.91645
APOE4 carriers × time	0.19189	0.09692	0.048	−0.01589	0.00944	0.0926	−0.00242	0.00500	0.62848
Cluster 2 × time	0.70912	0.09689	< 0.001	−0.04347	0.00949	< 0.001	−0.01746	0.00505	< 0.001
Cluster 3 × time	2.00695	0.16203	< 0.001	−0.09211	0.01549	< 0.001	−0.03043	0.00756	< 0.001
Cluster 4 × time	3.43357	0.32123	< 0.001	−0.12947	0.03251	< 0.001	−0.02434	0.01518	0.11045
	CSF Aβ42			CSF t-tau			CSF p-tau		
Age × time	−0.0573	0.5792	0.9213	0.168	0.251	0.50419	−0.0212	0.0270	0.43234
Female gender × time	−5.7159	7.7435	0.4613	0.346	3.356	0.91793	−0.1093	0.3603	0.76202
Education × time	−0.8924	1.3041	0.4946	−0.579	0.571	0.31207	−0.0185	0.0607	0.76075
APOE4 carriers × time	−9.3435	8.0439	0.2468	−5.199	3.493	0.13829	−0.5993	0.3741	0.11084
Cluster 2 × time	9.7768	8.3837	0.2449	2.498	3.613	0.49024	0.3131	0.3897	0.42282
Cluster 3 × time	−3.9152	11.1462	0.7258	3.690	4.865	0.44909	−0.4855	0.5194	0.35108
Cluster 4 × time	−4.3862	25.9948	0.8662	17.413	11.405	0.12841	−3.0757	1.2123	0.01196

All models include the main effects of predictors, such as age, gender, years of education, APOE4 status, cluster membership, and years since baseline. However, for the sake of brevity, their coefficients are not displayed. Coefficients represent unstandardized values that indicate the yearly changes in each AD biomarker. APOE, Apolipoprotein E; MMSE, Mini-Mental State Examination; CDR-SB, Clinical Dementia Rating-sum of boxes; FAQ, Functional Activities Questionnaire; aVV, Adjusted ventricular volume; aHV, Adjusted hippocampal volume; FDG, fludeoxyglucose; Aβ, β-amyloid; t-tau, total tau; p-tau, phosphorylated tau.



interest in each of the three clusters differed relative to Cluster 1. All effects were significant relative to the reference group because none of the 95% confidence intervals contained 0. Additionally, the coefficients of Clusters 2–4 fell outside each other's intervals, indicating that they were significantly different from each other. For other models, the results were largely unchanged and consistent with the pairwise comparisons described above.

Clinical progression from MCI to dementia

Of the 291 MCI participants, two participants initially assigned to Cluster 4 in the cluster analysis (see Table 1) were reclassified as Cluster 3 due to the inadequacy of their small size as an independent group. Therefore, the cluster variable used in the survival analysis included 3 subgroups rather than 4 subgroups. Over a 5-year

follow-up period, 103 (35%) participants converted to dementia. **Figure 5** demonstrates the conversion rate to dementia using the Kaplan–Meier curves. A significant cluster difference in the conversion rate was observed using a log-rank test ($\chi^2[2] = 124$; $p < 0.001$). All pairwise comparisons between the 3 clusters were significant (all FDR-adjusted $p < 0.001$). With regard to the type of dementia, of the 103 MCI participants who progressed to dementia, 98 (95.1%) participants were diagnosed with AD dementia, while 5 (4.85%) progressed to non-AD dementias, including 2 with primary progressive aphasia, 1 with Parkinson's disease and Lewy body dementia features, 1 with progressive supranuclear palsy, and 1 who had experienced delirium in the past after being infected with the West Nile Virus.

Findings of multinomial logistic regression models

Multinomial logistic regression models were performed to examine the associations between potential predictors at baseline and cluster membership. **Table 3** shows the summary of multinomial logistic regression models. We built four models and assessed model fit using Nagelkerke's R^2 (Nagelkerke, 1991). In the base model, all predictors captured 47.5% of the variability in the Cluster outcome ($R^2 = 0.475$). The cognition model explained 56.7% of the variability in the Cluster outcome ($R^2 = 0.567$), indicating that the MMSE explained an additional 9.2% of the total Cluster variability. In the neurodegeneration model, all predictors captured 67.4% of the variability in the Cluster outcome ($R^2 = 0.674$), suggesting that aHV and FDG-PET explained an additional 10.7% of the total Cluster variability. Meanwhile, the AD biomarker model explained 68.8% of the variability in the Cluster outcome ($R^2 = 0.688$), indicating that CSF

A β 42 and p-tau explained only an additional 1.4% of the total Cluster variability. **Table 3** displays the adjusted odds ratios (aOR) and their 95% confidence intervals (CIs) for each model. For instance, in the AD biomarker model (the full model), compared with Cluster 1, there were consistent associations of membership to Cluster 2–4 with a clinical diagnosis of AD (aOR [95% CI]: 5.41 [2.54, 11.5], 12.6 [5.85, 27.1], and 44.9 [16.6, 121], respectively). MMSE, aHV, FDG-PET, and CSF p-tau were also consistently associated with cluster membership to Cluster 2–4. However, there were no significant associations between CSF A β 42 levels and cluster membership.

A simpler predictive model for enrichment of clinical trials involving early AD

Model simplification was conducted using stepwise variable selection with AIC as the stopping rule (see the seventh point in the statistical analyses section). The variables screened for inclusion were the same predictors as those in the AD biomarker model (see **Table 3**). The reduced model included clinical diagnosis, MMSE score, and FDG-PET, and partial effects plots with 95% pointwise confidence bands are presented in **Figure 6A**. This model resulted in an Area Under the Curve (AUC) of 0.912 (95% confidence intervals: 0.88–0.94; using DeLong statistics; **Figure 6B**). To evaluate the reliability of the model, a bootstrap overfitting-corrected calibration curve was generated with 1,000 iterations. **Figure 6C** demonstrates the excellent calibration of the model on the probability scale, as indicated by the close alignment of the calibration curve with the 45° line. Internal validation was performed using the bootstrap technique with 1,000 iterations, resulting in an optimism-corrected AUC of 0.910. A nomogram was created to facilitate an easy and practical estimation of the probabilities of experiencing steep cognitive decline in early AD (**Figure 6D**). Finally, simulated clinical trials were performed to investigate whether the nomogram would be used to enrich for trial populations in order to reduce sample size for a clinical trial involving individuals with early AD. As shown in **Figure 6E**, when including all eligible patients (no restrictions), the required sample sizes were 926.8 (95% CI: 822.6–1057.5). However, when including individuals predicted to experience steep cognitive decline using the nomogram, the required sample sizes were decreased to 400.9 (95% CI: 306.9–516.8).

Discussion

In this study, we observed highly variable cognitive trajectories in patients with early AD with evidence of abnormal amyloid in the brain already and demonstrated that AD does not affect different individuals in a uniform manner. In addition, our clustering analysis categorized patients with early AD into four subgroups and visualized these individual differences in patterns of cognitive trajectories. Overall, the findings of the current study provide evidence of (1) heterogeneous patterns of cognitive decline between patients with early AD, (2) associations of cognitive heterogeneity with other commonly used cognitive and functional measures, neurodegenerative markers, CSF AD biomarkers, and clinical progression from the MCI stage to a dementia diagnosis, (3) relationships of several baseline predictors with membership in the identified subtypes, and (4) the clinical




TABLE 3 Summary of multinomial logistic regression models.

Predictors	Clusters 2 vs 1		Clusters 3 vs 1		Clusters 4 vs 1	
	aOR (95% CI)	p-value	aOR (95%CI)	p-value	aOR (95%CI)	p-value
<i>The base model</i>						
Age, continuous (1-year increment)	1.03 (0.99–1.07)	0.2	1.04 (1.00, 1.10)	0.076	0.99 (0.93, 1.06)	0.8
Female gender, categorical (male as reference)	0.92 (0.55–1.53)	0.7	0.85 (0.44, 1.64)	0.6	1.37 (0.54, 3.51)	0.5
Education, continuous (1-year increment)	0.95 (0.86–1.04)	0.3	0.92 (0.81, 1.03)	0.15	0.96 (0.80, 1.14)	0.6
APOE4 carriers, categorical (noncarriers as reference)	1.70 (1.00–2.89)	0.050	1.84 (0.92, 3.68)	0.084	1.84 (0.67, 5.04)	0.2
Clinical diagnosis, categorical (MCI as reference)	23.8 (3.13–181)	0.002	215 (28.5, 1,613)	< 0.001	2,560 (223, 29,330)	< 0.001
<i>The cognition model</i>						
Age, continuous (1-year increment)	1.02 (0.98, 1.06)	0.4	1.03 (0.97, 1.08)	0.3	0.97 (0.91, 1.04)	0.3
Female gender, categorical (male as reference)	0.97 (0.57, 1.65)	> 0.9	0.97 (0.47, 1.99)	> 0.9	1.95 (0.69, 5.49)	0.2
Education, continuous (1-year increment)	0.99 (0.90, 1.09)	0.8	1.00 (0.87, 1.14)	> 0.9	1.08 (0.89, 1.32)	0.4
APOE4 carriers, categorical (noncarriers as reference)	1.57 (0.91, 2.71)	0.11	1.54 (0.73, 3.26)	0.3	1.73 (0.57, 5.22)	0.3
Clinical diagnosis, categorical (MCI as reference)	7.86 (0.97, 63.7)	0.054	23.4 (2.88, 189)	0.003	105 (8.2, 1,352)	< 0.001
MMSE, continuous (1-unit increment)	0.71 (0.60, 0.84)	< 0.001	0.49 (0.40, 0.61)	< 0.001	0.35 (0.26, 0.47)	< 0.001
<i>The neurodegeneration model</i>						
Age, continuous (1-year increment)	0.97 (0.93, 1.02)	0.3	0.97 (0.91, 1.03)	0.4	0.96 (0.88, 1.04)	0.3
Female gender, categorical (male as reference)	1.34 (0.74, 2.44)	0.3	1.6 (0.71, 3.61)	0.3	3.94 (1.21, 12.8)	0.023
Education, continuous (1-year increment)	0.95 (0.85, 1.06)	0.3	0.93 (0.81, 1.08)	0.4	0.99 (0.79, 1.25)	> 0.9
APOE4 carriers, categorical (noncarriers as reference)	1.27 (0.68, 2.35)	0.5	1.34 (0.58, 3.10)	0.5	1.86 (0.53, 6.52)	0.3
Clinical diagnosis, categorical (MCI as reference)	5.14 (0.6, 44.2)	0.14	12 (1.35, 107)	0.026	40.4 (2.69, 605)	0.008
MMSE, continuous (1-unit increment)	0.73 (0.61, 0.88)	< 0.001	0.52 (0.41, 0.66)	< 0.001	0.4 (0.29, 0.55)	< 0.001
aHV, continuous (1-unit increment)	0.43 (0.25, 0.72)	0.002	0.23 (0.11, 0.47)	< 0.001	0.28 (0.10, 0.82)	0.020
FDG-PET, continuous (1-unit increment)	0.01 (0.00, 0.06)	< 0.001	0.00 (0.00, 0.01)	< 0.001	0.00 (0.00, 0.00)	< 0.001
<i>The AD biomarker model</i>						
Age, continuous (1-year increment)	0.97 (0.94, 1.01)	0.12	0.97 (0.92, 1.02)	0.2	0.96 (0.90, 1.02)	0.2
Female gender, categorical (male as reference)	1.25 (0.66, 2.36)	0.5	1.39 (0.59, 3.28)	0.5	3.45 (0.98, 12.2)	0.054
Education, continuous (1-year increment)	0.96 (0.86, 1.08)	0.5	0.95 (0.82, 1.10)	0.5	0.99 (0.80, 1.23)	> 0.9
APOE4 carriers, categorical (noncarriers as reference)	0.91 (0.47, 1.76)	0.8	0.93 (0.39, 2.23)	0.9	1.14 (0.30, 4.30)	0.9
Clinical diagnosis, categorical (MCI as reference)	5.41 (2.54, 11.5)	< 0.001	12.6 (5.85, 27.1)	< 0.001	44.9 (16.6, 121)	< 0.001
MMSE, continuous (1-unit increment)	0.75 (0.66, 0.86)	< 0.001	0.54 (0.45, 0.64)	< 0.001	0.42 (0.32, 0.55)	< 0.001
aHV, continuous (1-unit increment)	0.42 (0.26, 0.69)	< 0.001	0.21 (0.11, 0.40)	< 0.001	0.23 (0.09, 0.60)	0.003
FDG-PET, continuous (1-unit increment)	0.01 (0.00, 0.05)	< 0.001	0.00 (0.00, 0.00)	< 0.001	0.00 (0.00, 0.00)	< 0.001
CSF Aβ42 levels, continuous (1-unit increment)	1.00 (1.00, 1.00)	0.051	1.00 (1.00, 1.00)	0.093	1.00 (0.99, 1.00)	0.15
CSF p-tau levels, continuous (1-unit increment)	1.02 (1.00, 1.05)	0.043	1.04 (1.01, 1.07)	0.019	1.06 (1.01, 1.1)	0.019

aOR, adjusted odds ratio; CI, confidence interval; APOE, Apolipoprotein E; MMSE, Mini-Mental State Examination; aHV, Adjusted hippocampal volume; FDG, fludeoxyglucose; Aβ, β-amyloid; p-tau, phosphorylated tau.




FIGURE 6
 A simplified model for enrichment of clinical trials involving early AD. **(A)** Shows the partial effects of three predictors in the simplified model. The partial effect of a predictor was investigated when holding all other predictors constant (clinical diagnosis = MCI; median MMSE score = 27; median FDG-PET = 1.158). **(B)** Demonstrates the ROC curve for the simplified model (clinical diagnosis, MMSE score, and FDG-PET). **(C)** Shows a bootstrap overfitting-corrected calibration curve. The closeness of the calibration curve to the 45° line illustrates an excellent calibration on the probability scale. **(D)** Displays a nomogram for the prediction of probabilities of experiencing steep cognitive decline over time based on 3 predictors in the simplified model. Instructions for using the nomogram: start by identifying the individual's clinical diagnosis (MCI or mild AD) and draw a vertical line to intersect on the Points axis (i.e., the top axis) to find the point. Repeat this process for the other predictors (MMSE and FDG-PET). Add up the points obtained for these three predictors. Locate the final sum on the Total Points scale and draw a vertical line downwards to identify the individual's predicted probability of experiencing steep cognitive decline on the Probability axis (i.e., the bottom axis). **(E)** Shows that the usage of the nomogram for enrichment resulted in a substantial reduction of required sample sizes in simulated clinical trials of early AD. For each column of the **(E)** (no restrictions vs. Predicted rapid decliners), three different plots are presented, including a boxplot, raw data points, and a density plot. MCI, Mild cognitive impairment; AD, Alzheimer's disease; MMSE, Mini-Mental State Examination; FDG, fludeoxyglucose; AUC, Area Under the Curve.

relevance of a nomogram in predicting the probabilities of experiencing steep cognitive decline based on the simplified model.

Our data-driven clustering method successfully categorized patients with early AD into biologically and clinically different

subgroups, as evidenced by the substantial differences in clinical characteristics and longitudinal changes in major AD biomarkers among the four identified clusters. Cluster 1, which represented approximately 31% of our study sample, showed a nearly negligible

rate of change in the ADAS-Cog-13 over a 5-year follow-up period (Figure 2A). This subgroup had significantly better baseline performance on other cognitive and functional measures, including the MMSE, CDR-SB, and FAQ, as well as a more favorable biomarker profile. These findings are consistent with previous studies conducted in clinical trial-based samples (Geifman et al., 2017; Levine et al., 2021) and the ADNI dataset (Ziegler et al., 2020), which also identified a similar subgroup with less impaired baseline performance. More importantly, CSF A β 42 levels of a number of individuals in cluster 1 were well above the level that would be regarded CSF A β 42 positive. In addition, cluster 1 was also experiencing minimal or no change in CSF A β 42 over time, further indicating that these individuals might not be on the AD trajectory. One reasonable strategy to maximize the chances of finding a successful treatment is to identify and remove the subgroup with a very low rate of cognitive decline in clinical trials (Edmonds et al., 2018). Therefore, improved stratification of early AD populations prior to recruitment in clinical trials could enhance the likelihood of detecting treatment efficacy and aid in the development of more efficient study designs.

We identified the largest early AD subgroup of the study sample, Cluster 2 ($n=141$, 34%), which initially performed worse on the ADAS-Cog-13, as shown by a greater intercept in Figure 2A, and exhibited a slightly faster rate of cognitive deterioration over time than Cluster 1. The two subgroups (Clusters 1 and 2) also differed significantly in their levels of AD-associated biomarkers, as indicated by Figures 3G–I. Specifically, participants in Cluster 2 had higher levels of CSF tau pathologies and lower levels of CSF A β 42 at baseline compared to those in Cluster 1. These findings are consistent with several longitudinal studies showing that unfavorable CSF biomarker profiles at baseline are predictive of future cognitive decline in patients with very mild AD dementia or in healthy older adults (Snider et al., 2009; Stomrud et al., 2010). Neurodegenerative markers, including aHV and FDG SUVRs (Figures 3E,F), were also significantly different between the two cognitive trajectories, suggesting that higher levels of aHV and FDG SUVRs (indicative of less severe neurodegeneration at baseline) are associated with slower cognitive deterioration over time in patients with early AD (de Leon et al., 2001; Lo et al., 2011). However, aVV did not show a significant difference between the two clusters (Figure 3D) despite that all three neuroimaging markers are considered indicators of neurodegeneration. These discrepancies may be attributed to the fact that ventricular enlargement is considered a more downstream event that is closely coupled with overt cognitive decline in the AD pathophysiological changes (Jack et al., 2004). Therefore, aVV may be a less sensitive marker at baseline compared to aHV and FDG SUVRs to predict future cognitive decline and may not be able to capture the subtle differences in cognitive decline between Clusters 1 and 2.

Clusters 3 ($n=108$, 26%) and 4 ($n=41$, 9%) demonstrated significantly steeper cognitive deterioration over time than Clusters 1 and 2, with Cluster 4 exhibiting the fastest cognitive decline trajectory (Figure 2A). These findings have important implications for clinical trials involving patients with early AD. In a clinical trial, assuming that the rates of cognitive decline exceed the level of background noise, randomization procedures may not necessarily lead to equal rates of decline in cognitive function between the treatment and placebo groups (Deaton and Cartwright, 2016). As a consequence, the variation in cognitive decline may affect the result of a trial. For

instance, although a statistically significant difference was found between the placebo and treatment groups in previous clinical trials, it cannot be entirely ruled out that the group difference may have been due to an over-representation of individuals from Clusters 3 and 4 (fast cognitive decliners) in the placebo group, or an over-representation of individuals from Clusters 1 and 2 (slow cognitive decliners) in the treatment group. One approach to overcome the problem of cognitive heterogeneity might thus be to recruit trial participants based on risk factors that are able to predict cognitive trajectories they may fall into subsequently. Future trials may consider enrolling individuals predicted to fall into Clusters 3 and 4 in order to increase the chances of success, enhance statistical power to observe treatment effects, and reduce cost, duration, and required sample size of a trial. One of the first steps to testing this strategy might be to build a multinomial logistic regression model to predict the cluster membership using baseline AD-associated markers. Our findings, as shown in Table 3, illustrated that in patients with early AD (with evidence of abnormal amyloid), clinical status, MMSE scores, aHV, FDG SUVRs, and CSF p-tau levels, which are well known factors related with rate of clinical progression (Blanco et al., 2023), were associated with the cluster membership. For instance, the AD biomarker model can explain 68.8% of the variability of the cluster membership. However, we did not observe a significant association between CSF A β 42 levels and the membership of cognitive trajectories in patients with early AD. This finding is somewhat expected and is probably explained by the fact that all included individuals were already amyloid-positive, and the variations in CSF A β 42 levels were not large enough to effectively capture the cognitive change. In addition, amyloid accumulation is thought of as a very early event that occurs prior to hypometabolism, hippocampal atrophy, or cognitive decline and has an early and subclinical effect on cognition (Lo et al., 2011). The simplified binary logistic regression model (Figure 6) may serve as the first crucial step in enrolling “right” participants (Cummings et al., 2019) and powering clinical trial design. Our model offers a valuable tool for the design and execution of new clinical trials. By complementing standard inclusion/exclusion criteria, they serve as an enhancement strategy to curate a cohort enriched with participants who are forecasted to exhibit cognitive decline. This approach simultaneously safeguards against the inadvertent enrollment of individuals anticipated to maintain cognitive stability, ensuring a more focused and efficient study population. Future studies that focus on replicating and validating our results in an independent cohort and testing whether our model is useful in the enrichment of clinical trials in early AD by identifying participants with faster cognitive trajectories are warranted.

The temporal ordering of changes in AD biomarkers can provide crucial information for our understanding of the pathophysiological alterations of the disease and for designing clinical trials for AD. The hypothetical cascade of AD biomarker changes has been proposed to follow a specific temporal ordering from amyloid deposition to tau aggregation, then to brain metabolic and structural changes, and finally to cognitive symptoms (Jack et al., 2013). However, this model remains to be tested. Our findings from these models largely support the hypothetical orderings of biomarker changes (Jack et al., 2013). Our analyses suggested that rates of cognitive progression were loosely coupled or even not associated with changes in markers presumed to be upstream events (i.e., changes in CSF A β 42 and tau

proteins) while were relatively more coupled with changes in markers presumed to indicate neurodegeneration and neuronal injury (i.e., ventricular enlargement, hippocampal atrophy, and brain hypometabolism). Specifically, our analyses did not observe a significant difference in the rates of change in CSF A β 42 or tau proteins between four cognitive trajectories (Figures 4G,H; Supplementary Figures S2G,H), indicating that amyloid accumulation or tau aggregation (CSF-based measures) may have reached a plateau at the MCI and mild dementia stages of the disease. The negative slope of Cluster 4 for CSF p-tau (Figure 4I; Supplementary Figure S2I) is unexpected. It may be possible that participants in Cluster 4 had the most severe cognitive impairment and the highest levels of CSF p-tau at baseline already, and thus the potential for CSF p-tau to further increase was limited, particularly at the later stages of the disease. Individuals in Cluster 4 who showed the most aggressive cognitive trajectory may also suffer from the most severely damaged blood–brain barrier (BBB), which could lead to the outflow of proteins from the CSF to the blood (Sweeney et al., 2018). However, the relationship between BBB integrity and AD pathologies is complex and not yet fully understood, and further research on this is needed. Further, the negative slope observed in this cluster could potentially be influenced by the limitations of a small sample size and short follow-up time. These factors may introduce variability errors, and thus, caution is warranted in interpreting the results. With respect to the markers presumed to represent neurodegenerative changes, our analyses found a more tightly coupled association between rates of cognitive decline and the magnitude of change in neurodegenerative biomarkers (i.e., aVV, aHV, and FDG SUVRs; see Figures 4D–F and Supplementary Figures S2D–F). Across these three neuroimaging markers, however, the magnitude of the associations of rates of cognitive decline with changes in these markers was distinct. For instance, all four cognitive trajectories exhibited significantly different slopes for ventricular enlargement, while the rates of hippocampal atrophy or brain hypometabolism of these four cognitive trajectories were not all different for each pairwise comparison, suggesting that ventricular enlargement is more closely coupled with cognitive changes than hippocampal atrophy or hypometabolism and thus maybe a more downstream event that follows hippocampal atrophy or hypometabolism (Jack et al., 2004, 2013). With regard to other cognitive and functional measures, as shown in Figures 4A–C and Supplementary Figures S2A–C (clusters 1 to 4 represented incremental rates of cognitive decline), rates of cognitive progression of the four clusters were the most closely coupled with changes in other cognitive and functional measures over time, as measured by MMSE, CDR-SB, and FAQ. These findings further supported the robustness of our clustering results as the pattern of the four cognitive trajectories was similar across distinct cognitive measures.

Several limitations of this study should be taken into account when interpreting our results. First, the individual trajectories on the ADAS-Cog-13 among patients with early AD were highly variable, as shown by the thin grey lines in Figure 2A. The cluster analysis used in this study should be interpreted as an exploratory analysis, rather than a confirmatory one. Indeed, it is possible that some patients could be categorized into a different cluster if the number of clusters changes. In this study, the 4-cluster solution was selected according to several considerations, including the BIC, the elbow method, and ensuring that each cluster had an adequate sample size. We acknowledge that a larger sample size of our study sample, especially the cluster 4 group,

would be needed to yield more robust and generalizable findings. However, our linear mixed effects models with distinct rates of cognitive changes as the independent variable and other cognitive and functional outcomes (i.e., MMSE, CDR-SB, and FAQ) yielded a very consistent profile of cognitive decline across different cognitive assessments (Figures 4A–C and Supplementary Figures S2A–C), strengthening the notion that the four cognitive trajectories identified in the cluster analysis were stable and robust. Second, in the cluster analysis, the longitudinal measurements on ADAS-Cog-13, rather than other AD markers, were used as our clustering variable due to the fact that the primary objective was to investigate the variations in cognitive decline among patients with early AD, and the ADAS-Cog-13 is one of the most commonly used assessment to track cognitive progression in AD clinical trials. Third, although changes in AD biomarkers over extended periods (e.g., several decades) are nonlinear (Jack et al., 2013), our linear mixed-effects models assumed that they were linear. However, during shorter periods (e.g., within a period of 5-year follow-up), AD biomarker changes can be modeled as linear functions because the nonlinearity appears to be minimal (Luo et al., 2022). The fourth limitation of our study is that our analysis was based on the ADNI cohort, a highly educated sample, with limited diversity with respect to racial and ethnic characteristics. This has restricted the generalizability of our findings, and thus independent and large cohorts, population-based studies in particular, are needed to replicate and validate our results. However, the ADNI study was designed to represent a potential AD clinical trial population, and, in this study, we applied a largely similar inclusion and exclusion criteria compared to those used in recent and current clinical trials of early AD. Hence, our results may seem to be relevant in the context of early AD clinical trials. Fifth, it could be argued that our data-driven approach was capturing disease stages instead of different rates of cognitive trajectories based on the observation that these four clusters had different intercepts. It should be noted that our strategy to ensure a similar disease stage was to select individuals with similar baseline levels of cognitive performance, as reflected by the inclusion criteria of a global CDR score of 0.5 or 1 and an MMSE score of 20–30. This group of individuals included in the current study is classified as early AD and is also commonly used in clinical trials (van Dyck et al., 2023). Furthermore, the observation that baseline cognitive performance was an important predictor for future cognitive decline is consistent with previous findings (Schaeffer et al., 2021). Therefore, it would be not unexpected to observe that those with more severe cognitive impairment at baseline are also more likely to decline in the future. However, worse cognitive performance at baseline does not necessarily determine future cognitive decline, as there are several other variables (Table 3) or unobserved factors that also contribute to the variance in cognitive decline. For example, 22 out of 141 individuals in the Cluster 2 were diagnosed as mild AD at baseline, while 40 out of 108 individuals in the Cluster 3 were diagnosed as MCI at baseline (Figure 2D). Finally, our decision to combine MCI and mild AD dementia into a single group was primarily driven by the recent success of clinical trials in the field of AD, which achieved statistical significance (Sims et al., 2023; van Dyck et al., 2023). These trials employed similar inclusion criteria, notably combining individuals with MCI and mild AD dementia who are amyloid-positive into an “early AD” group. Motivated by these studies, we undertook the present study to delve deeper into the heterogeneity of cognitive decline within this participant group. Our goal was to potentially

refine the recruitment process, thereby enhancing the likelihood of successful trials targeting patients in the early stages of AD.

Our study emphasizes the relevance of considering the heterogeneity of disease progression in early AD and provides further understanding of the temporal sequence of changes in AD biomarkers that correspond to different rates of cognitive decline. These findings have practical implications for the stratification of patients with early AD, potentially increasing the likelihood of identifying effective treatments for future AD clinical trials.

Data availability statement

The datasets presented in this article are not readily available because data used in the present study has been made publicly available by the ADNI in the Laboratory of Neuro Imaging (LONI) database (<https://adni.loni.usc.edu/>). The authors of this work are not authorized to share the data. Requests to access the datasets should be directed to <https://adni.loni.usc.edu/>.

Ethics statement

The studies involving humans were approved by each ADNI participant or authorized representative provided written informed consent and the institutional review board of each participating ADNI site approved the ADNI study. This study was conducted in accordance with the Declaration of Helsinki. This project was also submitted for review to the Institutional Review Board of Wenzhou Seventh People's Hospital. However, since the study did not involve direct contact with human subjects and utilized de-identified data, the Institutional Review Board of Wenzhou Seventh People's Hospital determined that formal review was not required. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

XW: Investigation, Methodology, Validation, Visualization, Writing – original draft. TY: Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft. DJ: Investigation, Validation, Visualization, Writing – original draft. WZ: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – review & editing. JZ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Conflict of interest

JZ serves as the Founder of Hangzhou Shansier Medical Technologies Co., Ltd. and holds shares in Hangzhou Shansier Medical Technologies Co., Ltd., which is dedicated to digitalizing clinical practice and research. WZ is employed by Hangzhou Shansier Medical Technologies Co., Ltd. and holds shares in Hangzhou Shansier Medical Technologies Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of *Frontiers*, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnagi.2024.1410544/full#supplementary-material>

References

- Akaike, H. (1974). A new look at the statistical model identification. *IEEE Trans. Autom. Control* 19, 716–723. doi: 10.1109/TAC.1974.1100705
- Bates, D. M., Machler, M., Bolker, B. M., and Walker, S. C. (2014). Fitting linear mixed-effects models using lme4. *J. Stat. Softw.* 67, 1–48. doi: 10.18637/jss.v067.i01
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. Royal Stat. Soc. Series B-methodol.* 57, 289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x
- Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E. J., Millettello, M. A., Andréasson, U., et al. (2016). Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β -amyloid (1–42) in human cerebrospinal fluid. *Alzheimers Dement.* 12, 517–526. doi: 10.1016/j.jalz.2015.09.009
- Blanco, K., Salcido, S., Orellana, P., Sauma-Pérez, T., León, T., Steinmetz, L. C. L., et al. (2023). Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer's disease. *Alzheimers Res. Ther.* 15:176. doi: 10.1186/s13195-023-01304-8
- Blanken, A. E., Jang, J. Y., Ho, J. K., Edmonds, E. C., Han, S. D., Bangen, K. J., et al. (2020). Distilling heterogeneity of mild cognitive impairment in the National Alzheimer Coordinating Center Database Using Latent Profile Analysis. *JAMA Netw. Open* 3:e200413. doi: 10.1001/jamanetworkopen.2020.0413
- Buuren, S. V., and Groothuis-Oudshoorn, K. G. M. (2011). MICE: multivariate imputation by chained equations in R. *J. Stat. Softw.* 45, 1–67. doi: 10.18637/jss.v045.i03
- Cano, S. J., Posner, H. B., Moline, M., Hurt, S. W., Swartz, J. E., Hsu, T., et al. (2010). The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. *J. Neurol. Neurosurg. Psychiatry* 81, 1363–1368. doi: 10.1136/jnnp.2009.204008
- Celeux, G., and Govaert, G. (1992). A classification EM algorithm for clustering and two stochastic versions. *Comput. Stat. Data Anal.* 14, 315–332. doi: 10.1016/0167-9473(92)90042-E
- Cohen, C. I., Reisberg, B., and Yaffe, R. (2024). Global cognitive trajectory patterns in Alzheimer's disease. *Int. Psychogeriatr.* 36, 200–209. doi: 10.1017/S1041610222000047
- Cummings, J., Feldman, H. H., and Scheltens, P. (2019). The "rights" of precision drug development for Alzheimer's disease. *Alzheimers Res. Ther.* 11:76. doi: 10.1186/s13195-019-0529-5
- De Leon, M. J., Convit, A., Wolf, O., Tarshish, C. Y., Desanti, S., Rusinek, H., et al. (2001). Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). *Proc. Natl. Acad. Sci. USA* 98, 10966–10971. doi: 10.1073/pnas.191044198
- Deaton, A., and Cartwright, N. (2016). Understanding and misunderstanding randomized controlled trials. *Soc. Sci. Med.* 210, 2–21. doi: 10.1016/j.socscimed.2017.12.005
- Edmonds, E. C., Ard, M. C., Edland, S. D., Galasko, D. R., Salmon, D. P., and Bondi, M. W. (2018). Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: a secondary analysis of the ADCS vitamin E and donepezil in MCI study. *Alzheimer's Dement.* 4, 11–18. doi: 10.1016/j.trci.2017.11.001
- Edmonds, E. C., Smirnov, D. S., Thomas, K. R., Graves, L. V., Bangen, K. J., Delano-Wood, L., et al. (2021). Data-driven vs consensus diagnosis of MCI: enhanced sensitivity for detection of clinical, biomarker, and Neuropathologic outcomes. *Neurology* 97, e1288–e1299. doi: 10.1212/WNL.0000000000012600
- Fogel, D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. *Contemp. Clin. Trials Commun.* 11, 156–164. doi: 10.1016/j.conctc.2018.08.001
- Folstein, M. F., Folstein, S. E., and Mchugh, P. R. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* 12, 189–198. doi: 10.1016/0022-3956(75)90026-6
- Gamberger, D., Lavrač, N., Srivatsa, S., Tanzi, R. E., and Doraiswamy, P. M. (2017). Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease. *Sci. Rep.* 7:6763. doi: 10.1038/s41598-017-06624-y
- Geifman, N., Kennedy, R. E., Schneider, L. S., Buchan, I. E., and Brinton, R. D. (2017). Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. *Alzheimers Res. Ther.* 10:4. doi: 10.1186/s13195-017-0332-0
- Genolini, C., Alacoque, X., Sentenac, M., and Arnaud, C. (2015). Kml and kml3d: R packages to cluster longitudinal data. *J. Stat. Softw.* 65, 1–34. doi: 10.18637/jss.v065.i04
- Giraldo, D. L., Sijbers, J., and Romero, E. (2021). Quantification of cognitive impairment to characterize heterogeneity of patients at risk of developing Alzheimer's disease dementia. *Alzheimers Dement (Amst)* 13:e12237. doi: 10.1002/dad2.12237
- Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeblerlein, S. L. B., et al. (2018). NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 14, 535–562. doi: 10.1016/j.jalz.2018.02.018
- Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., et al. (2013). Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol.* 12, 207–216. doi: 10.1016/S1474-4422(12)70291-0
- Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., et al. (2010a). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol.* 9, 119–128. doi: 10.1016/S1474-4422(09)70299-6
- Jack, C. R., Shiung, M. M., Gunter, J. L., O'Brien, P. C., Weigand, S. D., Knopman, D. S., et al. (2004). Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. *Neurology* 62, 591–600. doi: 10.1212/01.WNL.0000110315.26026.EF
- Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G. Q., et al. (2010b). Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. *Brain* 133, 3336–3348. doi: 10.1093/brain/awq277
- Jutten, R. J., Sikkes, S. A. M., Van Der Flier, W. M., Scheltens, P., Visser, P. J., and Tijms, B. M. (2021). Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity. *Neurology* 96, e2673–e2684. doi: 10.1212/WNL.00000000000012022
- Kim, Y. J., Cho, S. K., Kim, H. J., Lee, J. S., Lee, J., Jang, Y. K., et al. (2019). Data-driven prognostic features of cognitive trajectories in patients with amnesic mild cognitive impairments. *Alzheimers Res. Ther.* 11:10. doi: 10.1186/s13195-018-0462-z
- Kim, B. S., Jun, S., and Kim, H. (2023). Cognitive trajectories and associated biomarkers in patients with mild cognitive impairment. *J. Alzheimers Dis.* 92, 803–814. doi: 10.3233/JAD-220326
- Kim, Y. J., Kim, S. E., Hahn, A., Jang, H., Kim, J. P., Kim, H. J., et al. (2023). Classification and prediction of cognitive trajectories of cognitively unimpaired individuals. *Front. Aging Neurosci.* 15:1122927. doi: 10.3389/fnagi.2023.1122927
- Kim, S. J., Woo, S.-Y., Kim, Y. J., Jang, H., Kim, H. J., Na, D. L., et al. (2022). Development of prediction models for distinguishable cognitive trajectories in patients with amyloid positive mild cognitive impairment. *Neurobiol. Aging* 114, 84–93. doi: 10.1016/j.neurobiolaging.2022.02.012
- Landau, S. M., Breault, C., Joshi, A. D., Pontecorvo, M. J., Mathis, C. A., Jagust, W. J., et al. (2013). Amyloid- β imaging with Pittsburgh compound B and Florbetapir: comparing radiotracers and quantification methods. *J. Nuclear Med.* 54, 70–77. doi: 10.2967/jnumed.112.109009
- Lawless, J. F., and Singhal, K. (1978). Efficient screening of nonnormal regression models. *Biometrics* 34:318. doi: 10.2307/2530022
- Lee, J. S., Cho, S.-K., Kim, H. J., Kim, Y. J., Park, K.-C., Lockhart, S. N., et al. (2018). Prediction models of cognitive trajectories in patients with nonamnesic mild cognitive impairment. *Sci. Rep.* 8. doi: 10.1038/s41598-018-28881-1
- Levine, S. Z., Goldberg, Y., Yoshida, K., Samara, M., Cipriani, A., Iwatsubo, T., et al. (2021). Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil. *Eur. Psychiatry* 64:e16. doi: 10.1192/j.eurpsy.2021.8
- Lo, R. Y., Hubbard, A. E., Shaw, L. M., Trojanowski, J. Q., Petersen, R. C., Aisen, P. S., et al. (2011). Longitudinal change of biomarkers in cognitive decline. *Arch. Neurol.* 68, 1257–1266. doi: 10.1001/archneurol.2011.123
- Luo, J., Agboola, F., Grant, E., Morris, J. C., Masters, C. L., Albert, M. S., et al. (2022). Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. *Brain* 145, 4459–4473. doi: 10.1093/brain/awac238
- Marshall, G. A., Zoller, A. S., Lorus, N., Amariglio, R. E., Locascio, J. J., Johnson, K. A., et al. (2015). Functional activities questionnaire items that best discriminate and predict progression from clinically Normal to mild cognitive impairment. *Curr. Alzheimer Res.* 12, 493–502. doi: 10.2174/156720501205150526115003
- Mckhann, G., Drachman, D. A., Folstein, M. F., Katzman, R., Price, D. L., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease. *Neurology* 34:939. doi: 10.1212/WNL.34.7.939
- Nagelkerke, N. J. D. (1991). A note on a general definition of the coefficient of determination. *Biometrika* 78, 691–692. doi: 10.1093/biomet/78.3.691
- Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., and Filos, S. (1982). Measurement of functional activities in older adults in the community. *J. Gerontol.* 37, 323–329. doi: 10.1093/geronj/37.3.323
- Qiu, Y., Jacobs, D. M., Messer, K. S., Salmon, D. P., and Feldman, H. H. (2019). Cognitive heterogeneity in probable Alzheimer disease. *Neurology* 93, e778–e790. doi: 10.1212/WNL.0000000000007967
- Rosen, W. G., Mohs, R. C., and Davis, K. L. (1984). A new rating scale for Alzheimer's disease. *Am. J. Psychiatry* 141, 1356–1364
- Rubin, D. B. (1989). "Multiple imputation for nonresponse in surveys." John Wiley & Sons, Inc. Available at: <https://onlinelibrary.wiley.com/doi/book/10.1002/9780470316696>
- Schaeferbeke, J. M., Gabel, S., Meersmans, K., Luckett, E. S., De Meyer, S., Adamczuk, K., et al. (2021). Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults. *Alzheimers Res. Ther.* 13:75. doi: 10.1186/s13195-021-00798-4

- Scheltens, N. M. E., Galindo-Garré, F., Pijnenburg, Y. A. L., Van Der Vlies, A. E., Smits, L. L., Koene, T., et al. (2015). The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. *J. Neurol. Neurosurg. Psychiatry* 87, 235–243. doi: 10.1136/jnnp-2014-309582
- Scheltens, N. M. E., Tijms, B. M., Heymans, M. W., Rabinovici, G. D., Cohn-Sheehy, B. I., Miller, B. L., et al. (2018). Prominent non-memory deficits in Alzheimer's disease are associated with faster disease progression. *J. Alzheimer's Dis.* 65, 1029–1039. doi: 10.3233/JAD-171088
- Scheltens, N. M. E., Tijms, B. M., Koene, T., Barkhof, F., Teunissen, C. E., Wolfsgruber, S., et al. (2017). Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. *Alzheimers Dement.* 13, 1226–1236. doi: 10.1016/j.jalz.2017.03.002
- Schindler, S. E., Gray, J. D., Gordon, B. A., Xiong, C., Batrla-Utermann, R., Quan, M., et al. (2018). Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. *Alzheimers Dement.* 14, 1460–1469. doi: 10.1016/j.jalz.2018.01.013
- Schwarz, G. (1978). Estimating the dimension of a model. *Ann. Stat.* 6, 461–464. doi: 10.1214/aos/1176344136
- Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayio, P., Sparks, J., et al. (2023). Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA* 330, 512–527. doi: 10.1001/jama.2023.13239
- Snider, B. J., Fagan, A. M., Roe, C., Shah, A. R., Grant, E. A., Xiong, C., et al. (2009). Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. *Arch. Neurol.* 66, 638–645. doi: 10.1001/archneurol.2009.55
- Stomrud, E., Hansson, O., Zetterberg, H., Blennow, K., Minthon, L., and Londos, E. (2010). Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. *Arch. Neurol.* 67, 217–223. doi: 10.1001/archneurol.2009.316
- Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., and Zlokovic, B. V. (2018). The role of brain vasculature in neurodegenerative disorders. *Nat. Neurosci.* 21, 1318–1331. doi: 10.1038/s41593-018-0234-x
- Team, R. Core (2014). R: a language and environment for statistical computing. *MSOR Connect.* 1.
- Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. (2023). Lecanemab in early Alzheimer's disease. *N. Engl. J. Med.* 388, 9–21. doi: 10.1056/NEJMoa2212948
- Van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soinenen, H., et al. (2012). Injury markers predict time to dementia in subjects with MCI and amyloid pathology. *Neurology* 79, 1809–1816. doi: 10.1212/WNL.0b013e3182704056
- Venables, W. N., and Ripley, B. D. (2002). “Modern applied statistics with S fourth edition”. Springer. Available at: <https://link.springer.com/book/10.1007/978-0-387-21706-2>
- Vos, S. J. B., Verhey, F. R. J., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., et al. (2015). Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. *Brain J. Neurol.* 138, 1327–1338. doi: 10.1093/brain/awv029
- Wang, X., Ye, T., Zhou, W., and Zhang, J. (2023). Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. *Alzheimers Res. Ther.* 15:57. doi: 10.1186/s13195-023-01205-w
- Williams, M. M., Storandt, M., Roe, C. M., and Morris, J. C. (2013). Progression of Alzheimer's disease as measured by clinical dementia rating sum of boxes scores. *Alzheimers Dement.* 9, S39–S44. doi: 10.1016/j.jalz.2012.01.005
- Ziegler, S., Maier, C., and Reichenbach, A. (2020). Stratification of patients with Alzheimer's disease based on longitudinal neuropsychological tests. *IEEE Int. Conf. Healthc. Inform.* 2020, 1–7. doi: 10.1109/ICHI48887.2020.9374343